SHANGHAI--(BUSINESS WIRE)--Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at ...
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer. This is an ASCO Meeting ...
NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary ...
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a ...
ABL Bio, a company specializing in bispecific antibodies, announced on September 26 that it has received a decision of patent grant for its 4-1BB monoclonal antibody and its applications in South ...
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of ...
Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody ...
First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors China sites to join the dose expansion part of the study to accelerate TJ-CD4B ...
Conventionally, the first and second stimulation signals in vitro, simulating the process in vivo, are achieved using anti-CD3 antibody, anti-CD28 antibody, or CD3/CD28 magnetic beads, along with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results